Resources from the same session
3849 - Distant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-Year analysis in phase III NEOS trial
Presenter: Hiroji Iwata
Session: Proffered paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
5935 - Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort
Presenter: Barbara Pistilli
Session: Proffered paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
5643 - PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results
Presenter: Peter Hall
Session: Proffered paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
1728 - Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized ShortHER trial.
Presenter: Maria Vittoria Dieci
Session: Proffered paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
1423 - High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with _4 involved axillary lymph nodes (ALN): 20-year follow-up of a randomized phase 3 study
Presenter: Tessa Steenbruggen
Session: Proffered paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Proffered paper session - Breast cancer, early stage - Invited Discussant one LBA TBC, 186O and 187O
Presenter: Javier Cortes Castan
Session: Proffered paper session - Breast cancer, early stage
Resources:
Slides
Webcast